ResMed (WBO:RMD) Cyclically Adjusted FCF per Share: €5.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:RMD ResMed Inc WBO:RMD
91 GF Score
Price €174.35
GF Value €240.48
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted FCF per Share?

ResMed WBO:RMD +3.84% 91 Cyclically Adjusted FCF per Share is €5.00 as of Mar. 2026. GuruFocus rates WBO:RMD with a GF Score™ of 91/100 and a GF Value™ of €240.48 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ResMed's adjusted free cash flow per share for the three months ended in Mar. 2026 was €3.054. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €5.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted FCF Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 15.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 12.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ResMed was 100.00% per year. The lowest was 8.30% per year. And the median was 20.10% per year.

As of today (2026-07-16), ResMed's current stock price is €174.35. ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €5.00. ResMed's Cyclically Adjusted Price-to-FCF of today is 34.87.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.30. And the median was 51.55.


ResMed  (WBO:RMD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ResMed's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=174.35/5.00
=34.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.30. And the median was 51.55.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ResMed Cyclically Adjusted FCF per Share Related Terms


ResMed Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted FCF per Share Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.68 3.24 3.27 3.99 4.41

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.45 4.41 4.63 4.79 5.00

WBO:RMD vs MDLN, WST, BDX: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted Price-to-FCF falls into.


WBO:RMD
91GF Score
ResMed Inc WBO:RMD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.054/330.2130*330.2130
=3.054

Current CPI (Mar. 2026) = 330.2130.

ResMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.792 241.018 1.085
201609 0.434 241.428 0.594
201612 0.688 241.432 0.941
201703 0.332 243.801 0.450
201706 0.746 244.955 1.006
201709 0.443 246.819 0.593
201712 0.671 246.524 0.899
201803 0.755 249.554 0.999
201806 0.651 251.989 0.853
201809 0.193 252.439 0.252
201812 0.664 251.233 0.873
201903 0.752 254.202 0.977
201906 0.718 256.143 0.926
201909 0.861 256.759 1.107
201912 0.260 256.974 0.334
202003 1.290 258.115 1.650
202006 1.878 257.797 2.406
202009 0.728 260.280 0.924
202012 0.740 260.474 0.938
202103 0.965 264.877 1.203
202106 1.108 271.696 1.347
202109 -0.564 274.310 -0.679
202112 1.085 278.802 1.285
202203 0.403 287.504 0.463
202206 0.303 296.311 0.338
202209 0.084 296.808 0.093
202212 0.621 296.797 0.691
202303 1.593 301.836 1.743
202306 1.242 305.109 1.344
202309 1.559 307.789 1.673
202312 1.543 306.746 1.661
202403 2.364 312.332 2.499
202406 2.605 314.175 2.738
202409 1.868 315.301 1.956
202412 1.846 315.605 1.931
202503 3.486 319.799 3.600
202506 2.977 322.561 3.048
202509 2.387 324.800 2.427
202512 1.781 324.054 1.815
202603 3.054 330.213 3.054

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €5.00 mean?
ResMed (WBO:RMD) has a Cyclically Adjusted FCF per Share of €5.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted FCF per Share too high?
ResMed's current Cyclically Adjusted FCF per Share is €5.00. Overall, ResMed has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted FCF per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted FCF per Share of €5.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted FCF per Share is €5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (WBO:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is €240.48, compared to a current price of €174.35 — trading 27.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €5.00. ResMed's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ResMed (WBO:RMD), the current Cyclically Adjusted FCF per Share is €5.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (WBO:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of €174.35 is trading 27.5% below its estimated GF Value™ of €240.48. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for WBO:RMD:

  • Cyclically Adjusted FCF per Share: €5.00
  • GF Value™: €240.48 vs. price of €174.35 (27.5% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the WBO:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
91GF Score

Get the complete analysis for WBO:RMD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€174.35
Price
€240.48
GF Value